
**Abemaciclib** MONARCH 3



## Abemaciclib MONARCH 3 Abemaciclib MONARCH 3 PRFLIMINARY SCORE **CURATIVE CURATIVE NON-CURATIVE NON-CURATIVE** Overall Survival **ADJUSTMENTS** Quality of life Progression-Free Survival QoL not clinically significant Serious and disabling adverse effects Overall Response Rate / Duration of Response Other adjustments INFORMATION growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer Experimental Arm: Abemaciclib + Aromatase inhibitor Control Arm: Placebo + aromatase inhibitor





© 2023 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.